HeLa 229

Isolated as a clonal subline from the parental HeLa strain, HeLa 229 retains the aggressive epithelial phenotype and aneuploid karyotype of its origin while exhibiting a distinctive, application‑defining functional divergence: relative insusceptibility to poliovirus coupled with superior permissiveness for obligate intracellular bacterial pathogens.

Unlike the parental line, HeLa 229 displays marked resistance to poliovirus 1, yet remains fully susceptible to human adenovirus 7 and vesicular stomatitis virus. This selective permissiveness enables controlled virological studies where poliovirus interference must be minimized.

Under standardized DEAE‑dextran/cycloheximide treatment, HeLa 229 supports high‑yield propagation of Chlamydia trachomatis and Chlamydia pneumoniae. It produces significantly greater inclusion counts and a threefold higher infectious progeny yield than the reference McCoy cell line, establishing it as the superior system for chlamydial isolation, diagnostics, and vaccine research.

HeLa 229 is documented to readily adapt to suspension culture, a trait not universally shared by adherent cervical carcinoma lines. This capability, combined with its robust doubling time (~26 h), facilitates scalable biomanufacturing and high‑throughput screening platforms.

These attributes distinguish HeLa 229 not as a generic HeLa substitute, but as a phenotypically honed tool-balancing permissiveness and resistance in ways precisely calibrated for chlamydiology, viral receptor mapping, and suspension‑adapted oncological cell engineering.